US 12,116,380 B2
Phospholipid compounds and methods of making and using the same
Byoung-Kwon Chun, Pleasanton, CA (US); Michael O. Clarke, Redwood City, CA (US); Deeba Ensan, Foster City, CA (US); Rao V. Kalla, Foster City, CA (US); Richard L Mackman, Millbrae, CA (US); Jagadeesh N. Manda, Santa Clara, CA (US); Devan Naduthambi, San Bruno, CA (US); and Dustin S. Siegel, Half Moon Bay, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Aug. 16, 2022, as Appl. No. 17/820,183.
Claims priority of provisional application 63/313,633, filed on Feb. 24, 2022.
Claims priority of provisional application 63/234,515, filed on Aug. 18, 2021.
Prior Publication US 2023/0212199 A1, Jul. 6, 2023
Int. Cl. C07F 9/09 (2006.01); A61K 31/706 (2006.01); A61P 31/14 (2006.01)
CPC C07F 9/095 (2013.01) [A61P 31/14 (2018.01)] 18 Claims
 
1. A compound of Formula V, or the pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein
n is 1 or 2;
m is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21;
each R1A is independently halo, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, or 5-10 membered heteroaryl containing one, two, or three heteroatoms selected from N and O;
R6 is H or —C(O)C1-C6 alkyl; and
R7 is H or —C(O)C1-C6 alkyl.